A Novel Parenteral Formulation For the Antiplatelet Agent Clopidogrel
Zubair A Karim,Natarajan Venkatesan,Harold J Ting,Guru Betageri,Fadi T Khasawneh
DOI: https://doi.org/10.1096/fasebj.30.1_supplement.lb532
2016-04-01
The FASEB Journal
Abstract:While platelets play a vital role in preventing excessive bleeding after injury (hemostasis), they also contribute to the genesis of thrombotic disorders. On this basis, research efforts have focused on identifying new targets and/or designing agents against these targets for therapeutic purposes. The P2Y 12 receptor (P2Y 12 R) remains one of the most attractive antiplatelet targets given that it plays a central role in platelet function. Furthermore, clopidogrel (Plavix®), which is a P2Y 12 R antagonist, is one of the most commonly prescribed drugs. However, one of the limitations facing antiplatelet therapeutic strategies is the lack of safe and/or suitable parenteral antiplatelet agents or formulations in order to complement oral agents. Based on these considerations, we designed and characterized the biological activity of a liposomal formulation (i.e., soya phosphatidylcholine, 50 mg; and cholesterol, 5 mg) of clopidogrel bisulfate under ex vivo and in vivo experimental settings. The liposomal clopidogrel was then administered by intravenous route (IV) to C57BL/6 mice through their tail vein, and our results revealed that one (1) hour post injection this formulation relative to vehicle control: 1. has the capacity to dose dependently (2 or 6 mg/kg) inhibit platelet aggregation induced by the agonist ADP; 2. this inhibitory effect was found to be selective given that it produced no detectable effects on aggregation mediated by a non‐ADP dependent pathway (i.e., the thromboxane receptor pathway stimulated by the agonist U46619); 3. prolong the tail bleeding time (modulate hemostasis), again in a dose‐dependent manner; and 4. confer protection (at 6 mg/kg) against the development of occlusive events using a carotid artery FeCl 3 injury‐induced thrombosis model. Collectively, we have successfully prepared and characterized a novel IV formulation for clopidogrel; which exhibits pharmacological activity on mouse platelets, at least 1 hour post administration, and under in vivo conditions. This formulation is expected to have a wide‐therapeutic application, given the limitations of the only currently available IV antiplatelet therapeutic agents (i.e., the platelet glycoprotein IIb IIIa antagonists). Support or Funding Information College of Pharmacy (to F.T.K), Western University of Health Sciences, Pomona, CA 91766
cell biology,biochemistry & molecular biology,biology